Skip to main content

Jin David's Form 4 filing

Fortress Biotech, Inc.FBIO · filed Nov 19, 2026

Accession no.
0001930732-26-000009
Filed
Nov 19, 2026, 5:54 PM ET
Trade date
Nov 17-19, 2026
Filing delay
2 days
Rule 10b5-1 plan
Not checked

This filing lists 3 non-derivative transactions. Open-market purchases total $87.8K. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Jin DavidCIK 0001930732Officer (Chief Financial Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Nov 17, 2026Common Stock, par value $0.001PPurchaseAcquired+15,000$1.72F1+$25,795.51,667,761Direct
Nov 18, 2026Common Stock, par value $0.001PPurchaseAcquired+25,000$1.91F1+$47,797.51,692,761Direct
Nov 19, 2026Common Stock, par value $0.001PPurchaseAcquired+7,605$1.87F1+$14,220.591,700,366Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

The prices reported in Column 4 are weighted average prices. The shares were purchased in multiple transactions in prices ranging from $1.71 to $1.72 on November 17, 2026, $1.8999 to $1.96 on November 18, 2026, and $1.865 to $1.87 on November 19, 2026, in each case inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this note.

Referenced by the price of 3 transactions in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)